(Q41847202)

13 October 2017

Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again (English)

1 reference

13 October 2017

Robert Eisenberg

1

1 reference

13 October 2017

15 May 2006

1 reference

Arthritis Research and Therapy

13 October 2017

1 reference

13 October 2017

8

1 reference

13 October 2017

3

1 reference

13 October 2017

108

1 reference

https://scigraph.springernature.com/pub.10.1186/ar1967

13 October 2017

0 references

cites work

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

The therapeutic potential of anti-CD20 "what do B-cells do?".

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Identification of the gene variations in human CD22.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

CD22 regulates thymus-independent responses and the lifespan of B cells.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1526641

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

3 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16732895

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16732895

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/AR1967

1 reference

PMC publication ID

1526641

Dimensions Publication ID

13 October 2017

0 references

1 reference

PMC publication ID

1526641

13 October 2017

PubMed publication ID

16732895

1 reference

PMC publication ID

1526641